KYOTO, Japan--(BUSINESS WIRE)-- Nidec Corporation (TOKYO: 6594; OTC US: NJDCY) (the “Company”) today announced that the Company resolved at a meeting of its Board of Directors held on May 24, 2024 to distribute retained earnings (date of record: March 31, 2024) in the form of an annual dividend as outlined below:
Determined
amount
Previous annual
dividends forecast
(Announced on
April 23, 2024)
(Reference) Annual... (continue reading...)
(Repurchases of Shares Pursuant to Item 1 of Article 459 (1) of the Companies Act of Japan)
KYOTO, Japan--(BUSINESS WIRE)-- Nidec Corporation (TOKYO:6594; OTC US: NJDCY) (the “Company”) announces today that its Board of Directors has authorized a new share repurchase plan at a meeting held on May 24, 2024, whereby the Company may repurchase up to 5 million shares in accordance with the Articles of Incorporation pursuant to Item 1 of Article 459 (1) of the... (continue reading...)
(Repurchases of Shares Pursuant to Item 1 of Article 459 (1) of the Companies Act of Japan)
KYOTO, Japan--(BUSINESS WIRE)-- Nidec Corporation (TOKYO: 6594; OTC US: NJDCY) (the ”Company”) today announces the status of the Company’s share repurchases under its repurchase plan in accordance with the Articles of Incorporation pursuant to Item 1 of Article 459 (1) of the Companies Act of Japan.
The Company also announces that the Company’s share repurchase... (continue reading...)
PARIS--(BUSINESS WIRE)-- Regulatory News:
Teleperformance SE’s (Paris: TEP) Combined General Meeting was held on May 23, 2024 in Paris under the chairmanship of Daniel Julien, Chairman and CEO of the Group.
Shareholders adopted all the resolutions submitted to their vote.
They notably approved:
- the 2023 parent company and consolidated financial statements;
- the proposed dividend of €3.85 per share: the ex-dividend date is May 28, 2024 and the payment... (continue reading...)
SAN JOSE, Calif.--(BUSINESS WIRE)-- Bloom Energy Corporation (NYSE: BE) today announced the pricing of its offering of $350.0 million aggregate principal amount of 3.00% green convertible senior notes due 2029 (the “notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering size was increased from the previously... (continue reading...)
More Business Wire
View Older Stories-
Innate Pharma Highlights Abstracts Selected for ASCO 2024 Annual Meeting
-
Elliptic Labs Signs Another Expansion License Contract with Top-4 Smartphone Customer Transsion
-
Scottish Sensor Technology Startup Novosound Targets Expansion in APAC
-
Hibiki Path Advisors Submitted Shareholder Proposals at the 53rd Annual General Meeting of Shareholders of Japan Pure Chemical Co., Ltd. Scheduled for June 25th, 2024
-
Kao Releases Progress Reports on its ESG Strategy—the Kirei Lifestyle Plan
-
iStaging reveals Next Generation MR experiences at VivaTech 2024.
-
Mitsubishi Electric to Establish Vietnamese JV for FA Products
-
The World's First Five-Terminal Flexible DC Transmission Project is Undergoing a Complete Overhaul
-
Celltrion receives European Commission approval of Omlyclo® (CT-P39), the first and only omalizumab biosimilar approved in Europe
-
The 2024 ESSENCE Festival of Culture™ Celebrates 30 Years of Loving Us with Evening Performances from USHER for a Special One-Night Only 20th Anniversary of Confessions Milestone Moment, Janet Jacks
-
Lee Leads Wire-to-Wire to Win MLF General Tire Heavy Hitters 2024 Presented by Bass Pro Shops on the Kissimmee Chain of Lakes
-
Alibaba Group Prices US$4,500 Million Offering of Convertible Senior Notes
-
Sensedia Launches AI Copilot to Accelerate and Enhance API Development
-
FDA Advisory Committee Panel Strongly Recommends Approval of Shield™ Blood Test for Colorectal Cancer Screening as a Primary Non-Invasive Screening Option
-
Limbach Holdings to Participate in Stifel Conference
-
FCPT Announces Sale Leaseback of Eight Mavis Tire Operated Properties for $20 Million
-
Aqua Pennsylvania Files Rate Request Based on Water and Wastewater Operations, Infrastructure Improvements and Repairs Across the Commonwealth
-
Browning West Announces Successful Replacement of Gildan Activewear’s Entire Board of Directors with Full Eight-Member Slate
-
Golden Entertainment Announces Repricing of Term Loan
-
Luskin Orthopaedic Institute for Children (LuskinOIC) Stand For Kids Gala Honors the Los Angeles Chargers and Students Run LA on the 50-yard Line of SoFi Stadium on June 8, 2024
-
Power Integrations to Present at Upcoming Investor Conferences
-
SSR Mining Announces Voting Results From 2024 Annual and Special Meeting of Shareholders
-
Pan American Silver Releases 2023 Sustainability Report
-
Crypto Specialist Bitwise’s First-Ever Spot Ethereum ETF Receives Key SEC Approval
-
Pei enters the MSCI COLCAP index
-
Oklo Partners with Wyoming Hyperscale to Deliver 100 Megawatts to its Data Centers
-
NW Natural Holdings and NW Natural CEO David H. Anderson Announces Retirement
-
Flatiron Health Announces Research to Be Presented at American Society of Clinical Oncology 2024 Annual Meeting
-
Puma Biotechnology Announces Publication of Alisertib Abstract Titles for the 2024 ASCO Annual Meeting
-
Nimbus Therapeutics Presents New Positive Monotherapy Phase 1/2 Clinical Data of HPK1 Inhibitor in Treatment of Advanced Solid Tumors at 2024 ASCO Annual Meeting
-
Barnes & Noble Education Announces Preliminary Fiscal Year 2024 Results
-
Breakthrough Data on Botensilimab/Balstilimab in MSS CRC Presented at the 2024 ASCO Annual Meeting
-
TelevisaUnivision Announces Pricing of $1.0 Billion Debt
-
Bicycle Therapeutics to Present Pharmacokinetic and Safety Evaluation of Lead BTC® Molecules in Phase 1/2 Trials at the 2024 ASCO Annual Meeting
-
TIGER Study Reports New TTFields Therapy Survival Results for Newly Diagnosed Glioblastoma Patients in Germany
-
Aulos Bioscience Provides Positive Interim Phase 1/2 Data From AU-007 at 2024 ASCO Annual Meeting
-
Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel
-
BNY Mellon Alcentra Global Multi-Strategy Credit Fund, Inc. Declares Distribution
-
Stellar Bancorp, Inc. Declares Quarterly Dividend and New Share Repurchase Program
-
KBRA Assigns AAA Rating, Stable Outlook to the New Mexico Finance Authority State Transportation Revenue Refunding Bonds (State Transportation Commission - Senior Lien), Series 2024A
-
NMDP and CIBMTR to Present New, Promising Stem Cell Transplantation Trial Data using Mismatched, Unrelated Donors at 2024 ASCO Annual Meeting
-
Verastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First
-
Incendia Therapeutics Announces Upcoming Presentation with PathAI at the 2024 American Society of Clinical Oncology Annual Meeting
-
Menarini Group Presents Updated Data from ELECTRA and ELEVATE Combination Studies of Elacestrant (ORSERDU®) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the ASCO 2024 Annual Meeting
-
AffyImmune Announces Confirmed Complete Response in Patient with Anaplastic Thyroid Cancer
-
NeraCare Announces Publication of Abstract on Clinical Validation of a Prognostic 7-Biomarker Assay for Prediction of Relapse in Patients with Early-Stage Cutaneous Melanoma at the 2024 American Socie
-
EMD Serono to Showcase Advances in the Science of Cancer With New Data Presented at ASCO 2024
-
Comvest Partners Announces $70 Million Senior Credit Facility For Nationwide Energy Partners to Support Growth Strategy
-
Obsidian Therapeutics Announces Positive Clinical Data from OBX-115 in Patients with Advanced Melanoma at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
-
City of Hope Researchers to Present Investigational Treatments for Colorectal, Kidney and Blood Cancers at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting